Greenwich LifeSciences (GLSI) Resumes $4.5M Share Buyback

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) announced today it would resume its existing Stock Repurchase Program.

Under the repurchase program previously authorized by the board of directors, Greenwich LifeSciences may repurchase its outstanding shares of common stock from time to time in open market or privately-negotiated transactions, including accelerated share repurchase transactions, block trades, or pursuant to 10b5-1 trading plans. Any repurchases will be at management’s discretion and will be subject to market conditions, the price of the Company’s shares and other factors. The stock repurchase program may be modified, suspended or terminated by the Board of Directors at any time.

The Company has approximately $4.5 million available under the current program. As of its most recently reported quarter-end March 31, 2022, the Company had 12,951,453 shares of common stock outstanding.

You May Also Be Interested In

• Playstudios announces 1-for-10 reverse stock split effective Sept. 30
• Baozun launches $10 million share repurchase program
• Lear boosts share buyback authorization to $1.5 billion through 2029